What is a good buy in point for MBIO

**Conclusion**: The buy point for MBIO is not clearly indicated by the available data. Here's an analysis based on the provided information:

1. **Clinical Trial Results**: MBIO's recent update on the Phase 1/2 trial of MB-106 shows promising safety and efficacy in treating Waldenstrom macroglobulinemia, with a 90% response rate. This positive development could be a catalyst for increased investor interest and potential stock price appreciation.
2. **Stock Performance**: MBIO's stock has experienced significant volatility, with a high trading volume and a strong session increase of 190% on a single day. However, the stock has also faced delisting notices due to trading below the required $1 minimum bid price. The stock's price has been influenced by market sentiment and recent news.
3. **Financial Indicators**: MBIO's P/E ratio is not available, which makes it difficult to assess the stock's valuation based on earnings. The company has a negative net fund flow of $12,608.13, indicating more selling than buying. The average price target is $2, with a strong buy consensus rating, suggesting some optimism among analysts.
4. **Technical Analysis**: The 50-day moving average is $0.3, and the 200-day moving average is $1.25. The stock has been trading below its 200-day moving average but has shown some signs of recovery, crossing above its 50-day moving average.
5. **Market Conditions**: The biotechnology sector can be volatile, and investors should consider the broader market conditions and their risk tolerance before investing in MBIO.

Given the lack of specific financial data and the high volatility, it is challenging to pinpoint a precise buy point for MBIO. Investors should closely monitor the company's progress in clinical trials, regulatory approvals, and any significant news that could impact the stock's performance. It is also advisable to consider the company's long-term growth prospects and the potential for further development of its pipeline products.